ELISA Kit for Preferentially Expressed Antigen In Melanoma (PRAME) is a premium-quality life science research product supplied by Torvigen for laboratory and scientific applications.
MAPE; OIP4; CT130; Cancer/Testis Antigen 130; Opa-interacting protein 4; Melanoma antigen preferentially expressed in tumors
Name Synonym
Preferentially Expressed Antigen In Melanoma
Uniprot
P78395
Field of Research
Tumor immunity
Applications
Enzyme-linked immunosorbent assay for Antigen Detection.
Organism Species
Homo sapiens (Human)
Format
48T, 96T, 96Tx5, 96Tx10, 96Tx100
Specificity
This assay has high sensitivity and excellent specificity for detection of Preferentially Expressed Antigen In Melanoma (PRAME) . No significant cross-reactivity or interference between Preferentially Expressed Antigen In Melanoma (PRAME) and analogues was observed.
Sensitivity
The minimum detectable dose of this kit is typically less than 0.113ng/mL
Detection Range
0.312-20ng/mL
Precision
Intra-assay Precision (Precision within an assay) : 3 samples with low, middle and high level Preferentially Expressed Antigen In Melanoma (PRAME) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays) : 3 samples with low, middle and high level Preferentially Expressed Antigen In Melanoma (PRAME) were tested on 3 different plates, 8 replicates in each plate. CV (%) = SD/meanX100 Intra-Assay: CV Inter-Assay: CV Inter-Assay: CV
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Assay Principle
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Preferentially Expressed Antigen In Melanoma (PRAME) . Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Preferentially Expressed Antigen In Melanoma (PRAME) . Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Preferentially Expressed Antigen In Melanoma (PRAME), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Preferentially Expressed Antigen In Melanoma (PRAME) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Assay Protocol
1. Prepare all reagents, samples and standards; 2. Add 100µ L standard or sample to each well. Incubate 2 hours at 37° C; 3. Aspirate and add 100µ L prepared Detection Reagent A. Incubate 1 hour at 37° C; 4. Aspirate and wash 3 times; 5. Add 100µ L prepared Detection Reagent B. Incubate 30 minutes at 37° C; 6. Aspirate and wash 5 times; 7. Add 90µ L Substrate Solution. Incubate 10-20 minutes at 37° C; 8. Add 50µ L Stop Solution. Read at 450nm immediately.
Assay Performance Time
3h
Method
Double-antibody Sandwich
Sample Type
Tissue homogenates, cell lysates, cell culture supernates and other biological fluids
